ArticleFrontiers in immunology2023

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME).

Tony Reid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.